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Objective: The assessment of response to lithium maintenance treatment in bipolar disorder (BD) is complicated by variable
length of treatment, unpredictable clinical course, and often inconsistent compliance. Prospective and retrospective
methods of assessment of lithium response have been proposed in the literature. In this study we report the key phenotypic
measures of the ‘‘Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder’’ scale
currently used in the Consortium on Lithium Genetics (ConLiGen) study.
Materials and Methods: Twenty-nine ConLiGen sites took part in a two-stage case-vignette rating procedure to examine
inter-rater agreement [Kappa (k)] and reliability [intra-class correlation coefficient (ICC)] of lithium response. Annotated first-
round vignettes and rating guidelines were circulated to expert research clinicians for training purposes between the two
stages. Further, we analyzed the distributional properties of the treatment response scores available for 1,308 patients using
mixture modeling.
Results: Substantial and moderate agreement was shown across sites in the first and second sets of vignettes (k=0.66 and
k=0.54, respectively), without significant improvement from training. However, definition of response using the A score as
a quantitative trait and selecting cases with B criteria of 4 or less showed an improvement between the two stages
(ICC1=0.71 and ICC2=0.75, respectively). Mixture modeling of score distribution indicated three subpopulations (full
responders, partial responders, non responders).
Conclusions: We identified two definitions of lithium response, one dichotomous and the other continuous, with moderate
to substantial inter-rater agreement and reliability. Accurate phenotypic measurement of lithium response is crucial for the
ongoing ConLiGen pharmacogenomic study.
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Introduction
Bipolar disorder (BD) is a lifelong and severe psychiatric illness
characterized by recurrences of episodes of depression and
hypomania/mania [1]. Lithium is among the first-line mainte-
nance treatments for BD [2,3], preventing relapses and recur-
rences of opposite polarity. In addition, lithium decreases the risk
of suicidal behaviour and all-cause mortality in mood disorders [4–
6].
Naturalistic analyses show that approximately one third of BD
patients achieve complete remission on lithium [7–14]. Lithium-
responsive BD patients have distinct clinical features, such as
episodicity of clinical course [15], absence of rapid cycling [16],
and a family history of BD [17], corresponding to the BD ‘‘core
phenotype’’ [18].
Despite a significant genetic component for lithium-responsive
BD [12,19], pharmacogenetic studies have not produced replicat-
ed results [20,21]. One possible explanation for the lack of
conclusive pharmacogenetic findings is the varying definition of
lithium response across the studies. Indeed, the assessment of
lithium maintenance treatment response, and consequently the
definition of the phenotype under study, is complicated by factors
inherent to the natural history of BD. The irregular clinical course
of BD [22] as well as variable treatment adherence [23] are only
few of the factors that contribute to the complexity in assessing the
response to lithium maintenance treatment.
To reduce the impact of the clinical heterogeneity of BD in
pharmacogenetics (and possibly to define genetically more
homogeneous subgroups of BD patients), researchers have
proposed to select prospectively followed patients on lithium
monotherapy with unequivocal clinical response [24,25]. Howev-
er, this may not be practical if large patient samples are needed. In
such cases, we need to rely on retrospective evaluation of
treatment response. Several such methods have been described
in the literature including the Affective Morbidity Index (AMI)
[26] and the Illness Severity Index [27]. The AMI takes into
account the duration and the severity of an episode, the latter
scored on a 4-point scale (0=no conspicuous affective disturbance,
1=mild depression or mania, 2=moderate depression or mania,
3=severe depression or mania). The area under the curve can be
calculated from these two variables and compared between
defined treatment periods. Similarly, the Illness Severity Index
measures the efficacy of lithium treatment in controlling mood
episodes. It is defined as the frequency of affective episodes prior to
Assessment of Lithium Response in Bipolar Disorder
PLOS ONE | www.plosone.org 2 June 2013 | Volume 8 | Issue 6 | e65636starting lithium adjusted for age at the time lithium was started
[27]. However, changes of affective morbidity might be not only a
result of the treatment, but could be due to other factors. In the
Consortium on Lithium Genetics (ConLiGen, www.ConLiGen.
org) study [28], we adopted the ‘‘Retrospective Criteria of Long-
Term Treatment Response in Research Subjects with Bipolar
Disorder’’ as the principal method of evaluation of the response to
lithium [12,13]. In addition to measuring the degree of clinical
improvement, this scale weighs clinical factors considered relevant
in determining whether the observed clinical change is in fact due
to the lithium treatment.
Since ConLiGen is an international multi-centre collaboration,
it has been crucial to assess the key phenotypic measures and the
response to long-term lithium treatment reliability across the
participating research groups. Here we present: 1) the results of the
reliability analysis of response to lithium treatment across the
participating centres, and 2) the distributional properties of the
scale scores. These two sets of findings have been instrumental in
obtaining stringent phenotypic definitions of lithium response.
These analyses are of particular importance in light of the
genome-wide association study (GWAS) currently being under-
taken by ConLiGen.
Materials and Methods
Assessment of Clinical Response to Lithium Treatment
The response to lithium treatment was measured using a
previously published and validated rating scale: the ‘‘Retrospec-
tive Criteria of Long-Term Treatment Response in Research
Subjects with Bipolar Disorder’’ [12,28]. Briefly, this scale
quantifies the degree of improvement in the course of treatment
(A criterion or A score) expressed as a composite measure of
change in frequency and severity of mood symptoms. The A
score is weighed against 5 factors (B criteria) which allow one to
determine if the observed improvement is a result of the
treatment rather than a spontaneous improvement or an effect
of additional medication. Specifically, the B criteria consider:
the number of episodes before/off the treatment (B1), the
frequency of episodes before/off the treatment (B2), the
duration of the treatment (B3), the compliance during period(s)
of stability (B4) and the use of additional medication during the
period of stability (B5). The total score (TS) is obtained by
subtracting the B score from the A score.
Table 1. Number of raters from the Consortium on Lithium Genetics (ConLiGen) centres participating in the two-stage case-
vignette rating procedure for inter-rater reliability and agreement.
ConLiGen centres First stage Second stage
University of Adelaide, Adelaide (Australia) 11
University of Sydney, Sydney (Australia) 10
University of Graz, Graz (Austria) 33
University of Campinas, Sa ˜o Paulo (Brasil) 33
Dalhousie University, Halifax (Canada) 92
University of Medellin, Medellin (Colombia) 44
Charles University, Prague (Czech Republic) 12
Institut national de la sante ´ et de la recherche me ´dicale, Paris (France) 1 1
University of Wu ¨rzburg, Wu ¨rzburg (Germany) 21
University of Go ¨ttingen, Go ¨ttingen (Germany) 2 0
Charite ´ - Universita ¨tsmedizin, Berlin (Germany) 1 2
Technische Universita ¨t Dresden,Dresden (Germany) 2 2
University of Cagliari, Sardinia (Italy) 33
University of Naples SUN, Naples (Italy) 12
The Japanese Collaborative Group on the Genetics of Lithium Response in Bipolar Disorder (Japan)* 4 4
University of Medical Sciences, Poznan ´ (Poland) 2 2
Obregia Psychiatric Hospital, Medical University, Bucharest (Romania) 2 2
Karolinska Institutet, Stockholm (Sweden) 11
University of Geneva, Geneva (Switzerland) 32
Academia Sinica, Taipei (Taiwan) 11
National Taiwan University, Taipei (Taiwan) 22
National Institute of Mental Health (USA) 42
The Johns Hopkins University, Baltimore (USA) 7 5
Mayo Clinic, Rochester (USA) 61
Massachusetts General Hospital, Boston (USA) 2 0
University of California, San Diego (USA) 20
Total number of raters 70 48
ConLiGen: Consortium on Lithium Genetics.
*Hokkaido, Osaka, Tokio, Riken Brain Science Institute.
doi:10.1371/journal.pone.0065636.t001
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the Assessment of Lithium Response
The agreement and reliability of the assessment of lithium
response between raters of 29 ConLiGen participating centres was
measured using a two-stage case-vignette rating procedure
(Table 1). Specifically, the study protocol had three phases: 1)
twelve standardized case vignettes prepared by investigators (M.A.,
J.G., C.S.) at Dalhousie University were circulated and rated by 70
investigators; 2) annotated first-round vignettes and rating
guidelines were circulated for training purposes after the first
stage; 3) sixteen additional more complex vignettes prepared by
senior researchers at Dalhousie University, Johns Hopkins
University School of Medicine, National Institute of Mental
Health (NIMH) and Academia Sinica of Taiwan (M.A., J.G., J.P.,
T.G.S., F.M., A.C.) were circulated and rated by 48 investigators
at the participating sites. The first set of vignettes was based
exclusively on BD patients who had been prospectively followed in
a specialty program and with detailed clinical information on the
course of illness and treatment history. The second set of vignettes
was heterogeneous and included patients treated in various
settings, some with limited clinical details assessed cross-section-
ally. Since raters had no prior knowledge of the rating scale, this
design allowed us to estimate the impact of training on agreement
and reliability of lithium response assessment. The rating
procedure was performed from April 2009 to October 2012.
The degree of concordance of lithium response definition was
assessed with Cohen’s kappa (k) [29] and intra-class correlation
(ICC) coefficient [30]. These analytical methods were applied to
the dichotomous and continuous definition of lithium response,
respectively. The k statistics (multiple raters with two outcomes)
were calculated with 95% confidence interval (CI) for each cut off
point of the TS scale in the range from 3 (non response to lithium)
to 8 (full response to lithium). Interpretation of the strength of
agreement was made according to Landis and Koch: poor (k
,0.00), slight (0.00–0.20), fair (0.21–0.40), moderate (0.41–0.60),
substantial (0.61–0.80), almost perfect (0.81–1.00) [31].
The quantitative scores of the treatment response scale were
analyzed in the first (ICC1) and second (ICC2) stage of ratings.
Specifically, we analyzed the TS (weighted clinical improvement),
the A score (uncorrected clinical improvement), the B score
(quantification of confounders), and the A score when B score #4.
The latter measure allows the identification of ‘‘valid cases’’
through selection at the B criteria. Subjects with B score #4 are
likely to have a clinical improvement causally related to lithium
treatment. The ICC was tested with the two-way random effects
model, that assumes a random sample of K investigators selected
from a larger population, and each rates N targets (i.e., case
vignettes) altogether, and the two-way mixed effects model, with
each target rated by each of the same K investigators, who are the
only ones of interest. For both models we calculated the single and
average measure reliability.
Analysis of the Distributional Properties of the Treatment
Response Scale
For the analysis of the distributional properties, we accessed TS
data of 1,308 BD patients from the NIMH centralized ConLiGen
phenotypic dataset.
Mixture analysis: frequentist and Bayesian
approach. We used mixture analysis to test whether we could
identify subgroups of patients according to the degree of response
to lithium as expressed by TS. The choice of the mixture model
that best fit the distribution of TS was made according to the
Akaike’s and Schwarz’s Bayesian information criteria (AIC and
BIC, respectively). The lower values of these two criteria indicated
the most parsimonious model that best fit the empirical function of
total score distribution. The analysis was performed using the
‘‘NMixEM’’ function implemented in the MixAk package [32] of
R software (version 2.13.2).
To verify the findings from the frequentist mixture analysis, we
performed the Bayesian mixture analysis employing a minimum
message length approach (MML) [33]. Specifically, we used the
Snob software [34] to test whether the distribution results from a
union of a number of ‘‘classes’’, where the distributions ‘‘within-
classes’’ are homogeneous and have a simple form, but vary
significantly ‘‘between-classes’’. The best fitting model was
indicated as the most parsimonious model (i.e., the one with the
lower cost expressed in nits, a specific measure unit conventionally
used to express the length message). The analysis was performed
using a measurement error equal to 2.5 empirically estimated by
plotting the distribution of TS.
Cut off point calculation. Cut off points were derived using
the theoretical TS function and calculating each data point’s
probability of belonging to each class. Specifically, once the
mixture model parameters were estimated, we calculated the
posterior probability of any data point x belonging to the i-th class
as
fx ;x [ Class ðÞ ~viN x;mi,si ðÞ =fx ðÞ
where v is the weight, m is the mean, s is the standard deviation.
The resulting probabilities were then compared in order to
establish which class the data point belonged to.
Results
Inter-rater Agreement and Reliability of the Assessment
of Lithium Response
Raters agreed to a substantial/moderate (first stage of case-
vignettes ratings) and moderate/fair (second stage of case-vignettes
ratings) degree in assessing lithium response as a dichotomous
variable (response/non response) (Table 2). We did not detect an
effect of training as shown by the lack of improvement in k.
Specifically, in the first stage of ratings, the k score showed a
substantial level of agreement when we considered the TS cut off
for response to lithium at 6 (k=0.65, 95% CI=0.36–0.85) and at
8( k=0.61, 95% CI=0.33–0.83). The highest k value was for the
TS cut off point of 7 (k=0.66, 95% CI=0.38–0.86). The second
stage of ratings had overall lower k values than the first indicating
a moderate level of agreement in the assessment of lithium
response (TS=6: k=0.51, 95% CI=0.29–0.73; TS=7: k=0.54,
95% CI=0.31–0.76; TS=8: k=0.54, 95% CI=0.28–0.76).
Again, the highest k value was found for the TS cut off point of
7. Details can be found in Table 2.
We then analyzed the inter-rater reliability for the continuous
definition of lithium response. We found that ICC values (two-way
random and mixed effects models, single measure) were higher in
the first stage of ratings for TS (ICC1=0.74 versus ICC2=0.55),
for A score (ICC1=0.66 versus ICC2=0.52) and for total B score
(ICC1=0.59 versus ICC2=0.34). However, the training improved
the inter-rater reliability of the A score when B score was #4
(ICC1=0.71 versus ICC2=0.75). These results are outlined in
Table 2.
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procedure: kappa and intra-class correlation analysis.
Assessment of lithium response First stage of ratings
1 Second stage of ratings
,
Dichotomous k (95% CI) z p k (95% CI) z p
TS cut off of 8 0.61 (0.33–0.83) 103.50 ,0.00001 0.54 (0.28–0.76) 68.06 ,0.00001
TS cut off of 7 0.66 (0.38–0.86) 112.18 ,0.00001 0.54 (0.31–0.76) 68.71 ,0.00001
TS cut off of 6 0.65 (0.36–0.85) 110.52 ,0.00001 0.51 (0.29–0.73) 64.54 ,0.00001
TS cut off of 5 0.58 (0.29–0.81) 99.23 ,0.00001 0.48 (0.25–0.71) 61.25 ,0.00001
TS cut off of 4 0.51 (0.20–0.78) 86.83 ,0.00001 0.42 (0.18–0.67) 52.94 ,0.00001
TS cut off of 3 0.40 (0.10–0.73) 68.25 ,0.00001 0.37 (0.13–0.66) 47.46 ,0.00001
Continuous ICC1 single measure
(95% CI)*
ICC1 average measure
(95% CI)*
ICC2 single measure
(95% CI)*
ICC2 average measure
(95% CI)*
TS 0.74 (0.59–0.89) 0.99 (0.98–1.00) 0.55 (0.36–0.80) 0.98 (0.96–0.99)
A score 0.66 (0.49–0.85) 0.99 (0.98–1.00) 0.52 (0.33–0.78) 0.98 (0.96–0.99)
Total B score 0.59 (0.41–0.81) 0.99 (0.98–1.00) 0.34 (0.19–0.64) 0.96 (0.92–0.99)
A score if total B score #4 0.71 (0.51–0.91) 0.99 (0.99–1.00) 0.75 (0.51–0.96) 0.99 (0.98–1.00)
TS: total score.
ICC: intra-class correlation.
CI: confidence interval.
*Mixed and random effects models.
170 raters.
"48 raters.
doi:10.1371/journal.pone.0065636.t002
Figure 1. Distribution of total and A scores in the Consortium on Lithium Genetics sample. Histogram plot of the scale scores in 1,308
bipolar disorder patients characterized for response to lithium maintenance treatment.
doi:10.1371/journal.pone.0065636.g001
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Distribution of the TS and joint distribution with score
A. Figure 1 illustrates the distribution of TS and A score in 1,308
BD patients characterized for lithium response. Two hundred
eighty three patients (21.6%) had TS equal to 0 and 104 patients
(8%) had A score equal to 0. In the whole sample the mean A
score 6 standard deviation] was 6.163.1 and the mean TS was
4.463.1. The joint distribution of TS and A scores is represented
in Figure 2. It illustrates the presence of two frequency peaks at the
extreme ends of the scale, namely at 0 and in the area comprised
between score A equal to 9 and TS equal to 8–10. A third peak is
present at the intersection of A score equal to 6 and TS of 4.
Mixture analysis: frequentist and bayesian
approach. The frequentist mixture analysis on TS showed a
best-fitting theoretical model of three normal components
(AIC=6467.69, BIC: 6498.75) (Figure 3A). A model with four
components did not improve the fit (AIC=6471.68,
BIC=6513.09, respectively). The mean TS was 0.7661.15 for
the non responder component, 4.661.15 for the partial responder
component and 8.361.15 for the full responder component, with
37%, 30%, and 33% of the population proportion, respectively.
The MML mixture analysis identified the most parsimonious
model of three normal components [mean, (SD), (proportion of
population)]: 0.5, (1.00), (32%); 4.5, (1.7), (38%); 8.4, (1.2), (30%)],
representing the non responder, the partial and the full responder
groups of patients. The model is displayed in Figure 3B.
Cut off point calculation. The functions of TS identified
with the two different mixture analysis approaches (frequentist and
Bayesian) were used to derive the probability of belonging and to
calculate the cut off point between the components. The
frequentist mixture model suggested two cut off points at TS=3
and TS=6.4. Considering the Bayesian MML theoretical
function, we obtained two cut off points at 2 and 7. These results
confirmed that TS $7 is the most appropriate cut off for the
definition of full response to lithium prophylaxis as suggested in
previous studies [12,13].
Discussion
The purpose of this study was to assess the key phenotypic
measures of response to lithium treatment in the large interna-
Figure 2. Joint distribution of total and A score in the Consortium on Lithium Genetics sample. Contour plot of the scale scores in 1,308
bipolar disorder patients characterized for response to lithium maintenance treatment.
doi:10.1371/journal.pone.0065636.g002
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two main analyses have been carried out: the inter-rater
agreement and reliability of lithium response definition across
the ConLiGen participating sites, and the analysis of the
distributional properties of the lithium treatment response scale
[12]. We found that two definitions of lithium response, one
dichotomous and the other continuous had moderate to substan-
tial inter-rater agreement and reliability. Specifically, the two-stage
case vignettes inter-rater reliability analysis pointed to the measure
of clinical improvement under lithium treatment expressed by the
A score and with selection of ‘‘valid cases’’ through a total B score
#4. This phenotypic definition of lithium response had a
substantial inter-rater reliability in the first stage of ratings
(ICC1=0.71) with further improvement in the second stage
(ICC2=0.75).
Figure 3. Empirical and theoretical distributions of the total score in the Consortium on Lithium Genetics sample. Frequentist, A, and
Bayesian minimum message length, B, mixture modeling identify three subpopulations of non responders (grey), partial responders (red), and full
responders (blue) in total scores of 1,308 bipolar disorder patients characterized for response to lithium maintenance treatment.
doi:10.1371/journal.pone.0065636.g003
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scale TS $7 was identified as the best cut off as shown by inter-
rater agreement k scores in the first (k=0.66) and second
(k=0.54) stages of case vignette ratings. Further, the analysis of
the distributional properties of the treatment response scale further
supported this dichotomous definition. In addition, this same
measure of lithium response has been previously proposed in
several clinical and genetic papers [12,13,35,36].
Some methodological considerations need to be made. For the
analysis of the distributional properties, we applied mixture
modeling, a method that has been extensively used in psychiatry
for the identification of patient subgroups, reducing phenotypic
heterogeneity and ultimately helping genetic research [37–39]. It
should be noted that this method is exploratory and it does not
identify the factors determining the differences between the
identified subgroups [40]. A validation of the model can be
obtained by comparison of the characteristics of each subgroup. In
the ConLiGen study, we plan to use the clinical correlates of
lithium response as external validators of the phenotypic measure
suggested by the mixture modeling. Such analysis will test and
compare the direction and magnitude of the association of a
number of clinical variables with lithium response in its
dichotomous and continuous definition.
Notably, the analysis of inter-rater reliability and agreement has
involved investigators belonging to different research groups with
different clinical backgrounds and training. Nevertheless, the use
of standardized case vignettes and the training procedures has
produced moderate to substantial agreement in the assessment of
lithium response. These findings are of importance, given the
evidence that even in the context of inpatient unit settings the
inter-rater agreement can be unsatisfactory [41].
We performed a two-stage case-vignettes procedure aimed at
testing the effect of training on the assessment of lithium response.
Contrary to our expectations, we only detected improvement in
the inter-rater reliability of lithium response expressed by the A
score and with selection of ‘‘valid cases’’ through a total B score
#4, but not in that expressed by TS or A score. Arguably, the
second set of vignettes described more complicated clinical cases
with comorbidities, lack of compliance and multiple treatments, all
factors that could have influenced the scoring of the B criteria.
Indeed, the ICC for the total B score decreased noticeably in the
second stage of ratings, implying an increased variability in rating
that impacted the discrimination among cases [42]. This
explanation is corroborated by the finding of the higher ICC2 of
A score with total B score #4. By applying this cut-off we
decreased the assessment variability ultimately increasing the
discrimination among cases.
Further, these findings confirm that patients with short duration
of lithium treatment, poor compliance, and concomitant medica-
tions are unlikely to be assessed reliably. This argues against the
inclusion of such complex, non-standard cases in pharmacoge-
nomic studies of lithium response. Finally, the higher inter-rater
agreement and reliability found in the first set of vignettes suggests
that the assessment of lithium response is reliable if sufficient
clinical details are available. On the other hand if the information
is limited, additional rater training will be of little help.
In conclusion, our findings support the use of two definitions of
lithium response for the pharmacogenomic GWAS currently being
performed by ConLiGen. Accurate phenotypic definitions of
treatment response are crucial in pharmacogenomic studies
[43,44]. Heterogeneity in the phenotype definition of treatment
response can be a problem especially when in the context of
psychiatric disorders. In the absence of other reliable clinical
measures of response to lithium, this study has suggested two
plausible phenotypic definitions that await application and
validation in other samples.
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